- Home
- IBIO vs NVNO Comparison
IBIO vs NVNO Comparison
Compare IBIO & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBIO
- NVNO
- Stock Information
- Founded
- IBIO 2008
- NVNO 1987
- Country
- IBIO United States
- NVNO United States
- Employees
- IBIO N/A
- NVNO N/A
- Industry
- IBIO Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- IBIO Health Care
- NVNO Health Care
- Exchange
- IBIO Nasdaq
- NVNO Nasdaq
- Market Cap
- IBIO 16.4M
- NVNO 16.7M
- IPO Year
- IBIO N/A
- NVNO N/A
- Fundamental
- Price
- IBIO $1.18
- NVNO $0.37
- Analyst Decision
- IBIO Strong Buy
- NVNO
- Analyst Count
- IBIO 4
- NVNO 0
- Target Price
- IBIO $4.50
- NVNO N/A
- AVG Volume (30 Days)
- IBIO 2.2M
- NVNO 897.9K
- Earning Date
- IBIO 11-12-2025
- NVNO 10-31-2025
- Dividend Yield
- IBIO N/A
- NVNO N/A
- EPS Growth
- IBIO N/A
- NVNO N/A
- EPS
- IBIO N/A
- NVNO N/A
- Revenue
- IBIO $500,000.00
- NVNO N/A
- Revenue This Year
- IBIO N/A
- NVNO N/A
- Revenue Next Year
- IBIO $33.34
- NVNO N/A
- P/E Ratio
- IBIO N/A
- NVNO N/A
- Revenue Growth
- IBIO 185.71
- NVNO N/A
- 52 Week Low
- IBIO $0.56
- NVNO $0.30
- 52 Week High
- IBIO $6.89
- NVNO $5.62
- Technical
- Relative Strength Index (RSI)
- IBIO 50.97
- NVNO 24.67
- Support Level
- IBIO $0.96
- NVNO $0.30
- Resistance Level
- IBIO $1.28
- NVNO $0.35
- Average True Range (ATR)
- IBIO 0.12
- NVNO 0.05
- MACD
- IBIO -0.03
- NVNO -0.01
- Stochastic Oscillator
- IBIO 54.68
- NVNO 12.18
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.